valacyclovir

P2, N=46, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026

P1, N=7, Completed, University of Alabama at Birmingham | Recruiting --> Completed | N=10 --> 7 | Trial completion date: Nov 2025 --> Jul 2024 | Trial primary completion date: Oct 2025 --> Jul 2024

P4, N=652, Completed, NYU Langone Health | Active, not recruiting --> Completed

Valacyclovir has the potential to be utilized in the clinical setting as an anti-viral drug molecule with anti-inflammatory properties. Future studies are needed to further confirm its activities on different immune system cell types.

P1, N=16, Recruiting, Shanghai BDgene Co., Ltd.

In a dose-dependent manner, acyclovir and Pavetta indica methanolic extract treatments abrogated the streptozotocin-induced behavioral and neurological abnormalities in rats. The potential therapeutic effects of PIME and acyclovir administration in intracerebroventricular-streptozotocin-treated rats may be attributed to its potential antiviral, antioxidant, and anti-inflammatory effects. The current study suggests that Pavetta indica methanolic extract and acyclovir are promising therapeutic targets against Alzheimer's disease.

P4, N=82, Recruiting, Dow University of Health Sciences

Urinary EBV was undetectable in any sample after valacyclovir treatment, and the decreases in urinary interleukin (IL)-1β (from 0.66 [0.55-0.82] pg/mL to 0.58 [0.55-0.64] pg/mL, p = 0.0034), IL-8 (from 6.81 [2.38 to 29.1] pg/mL to 4.33 [1.53-11.04] pg/mL, p = 0.0361), IL-10 (from 1.06 [0.94-1.18] pg/mL to 0.92 [0.88-1.02], p = 0.0086), and tumor necrosis factor-α (from 1.61 [1.50-1.72] pg/mL to 1.50 [1.44-1.55] pg/mL, p = 0.0079) were significant. Valacyclovir could relieve bladder pain, eliminate urinary EBV, and reduce bladder inflammation.

P2, N=60, Recruiting, Bateman Horne Center

P3, N=142, Recruiting, Centre Hospitalier Universitaire de Nice | Not yet recruiting --> Recruiting

P1, N=16, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024

P3, N=142, Not yet recruiting, Centre Hospitalier Universitaire de Nice

P2, N=50, Completed, Shanghai Institute Of Biological Products | Not yet recruiting --> Completed | N=240 --> 50 | Trial primary completion date: Mar 2023 --> Jul 2023

P2, N=50, Active, not recruiting, New York State Psychiatric Institute | Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2023 --> Nov 2024

P2, N=52, Completed, Candel Therapeutics, Inc. | Phase classification: P2a --> P2

Antimicrobial prophylaxis consisted of antifungal agents and valaciclovir...Fifty-nine pts (95.1%) received 7+3 idarubicin induction and 7 (11.3%) received midostaurin... In selected pts, outpt based AML H/IDAC consolidation therapy significantly reduced hospital length of stay compared with inpts. There was no impact on cycle length. Bacteremia and ICU admission rates were higher in outpts, and strategies such as remote monitoring or pre-emptive hospitalization could be considered.

Treatment options include plasmapheresis, dialysis, kidney transplantation and administration of the C5 antibody eculizumab...If CMV reactivation was detected, treatment was given with valacyclovir. In the case of cerebral progression, therapy with dabrafenib/trametinib was carried out after cerebral radiation with the BRAF V600K mutation...In this case, autoimmune nephritis, past Covid-19 infection and postoperative condition after laparotomy also come into consideration as summation factors. Interdisciplinary management of serious side effects is crucial for the outcome of affected patients

The described clinical picture was compatible with a herpetic infection, previously treated with valaciclovir for 7 days, which led to the clearance of the vesicular eruption but the persistence of the erythema...The patient experienced more clearance, after 8 months of system apremilast administration...It is therefore advisable that the therapeutic target in Wolf’s isotopic response should be the newly-emerging dermatosis. In our case, this is confirmed by the clinical improvement when acitretin was introduced in the therapeutic regimen.

Background: Venetoclax is a BCL-2 inhibitor approved for use in combination with Azacitadine or low dose Cytarabine (LDAC) in the front-line treatment of acute myeloid leukaemia (AML) in those aged over 75 or unfit for intensive induction...All subjects received anti-viral prophylaxis with valaciclovir and anti- fungal prophylaxis with Posaconazole, Voriconazole or Amphotericin...Demographics, Disease and Treatment Characteristics Median age, years (range) 67 (53-81) Sex 13 Male / 5 Female Type of AML (N) De Novo AML Secondary AML 4 14 ELN 2017 risk (N)ELN 2017 risk (N) Favourable Intermediate Adverse 2 7 9 Median number of prior lines of therapy (range) 2 (1-4) Cycles of Venetoclax (N) 1 cycle >1 cycle 11 7 Venetoclax combination (N) Monotherapy LDAC Azacitidine 3 11 4 Best response to Venetoclax (N=14) CR/CRi PR Stable or progressive disease 3 (21%) 1 (7%) 10 (71%) Table 2... This study show high rates of infection and related mortality in patients receiving Venetoclax therapy for R/R AML from neutropenic sepsis. Of note, there were 2 cases of PJP pneumonia and 2 IFIs suggesting anti-fungal and PJP prophylaxis should be strongly considered when using Venetoclax in R/R AML. The response rates after cycle 1 were modest with ORR 29% and median OS of 70 days.

P2, N=57, Active, not recruiting, The Methodist Hospital Research Institute | Trial primary completion date: Nov 2022 --> Jul 2022

The median OS increased by more than 2-fold in patients with clinical benefit. The therapy is a well-tolerated treatment in heavily pretreated mTNBC patients. Early detection of increased effector and effector memory CD8 T cells and myeloids correlate with response and non-response, respectively.

P2, N=57, Active, not recruiting, The Methodist Hospital Research Institute | Trial primary completion date: May 2022 --> Nov 2022

Temozolomide is administered to MGMT-methylation positive patients only. CONCLUSIONS The combination of CAN-2409 + nivolumab + SOC was well tolerated. Clinical follow-up and extensive biomarker analyses will provide a better understanding of the therapeutic potential of this approach.

The patient had received high-dose corticosteroids, tacrolimus, mycophenolate, and valacyclovir therapies, and had no lupus flares...These findings are consistent with EBV-associated smooth muscle tumors. EBV-associated smooth muscle tumors although rare, may occur with diffuse pattern of pulmonary involvement and should be considered in patients with solid organ transplant and incidental findings of multiple organ lesions on imaging.

After received valaciclovir, he switched to ibrutinib alone due to remained pancytopenia. Regarding to the literature, CLL/SLL cases transformed into T-cell lymphomas are rare and specially include PTCL, NOS and ALCL. Recently, Trimech et al. described 2 cases with composite AITL and CLL/ SLL and one case with same evolution as our case.

P2, N=57, Active, not recruiting, Jenny C. Chang, MD | Recruiting --> Active, not recruiting

A single intra-tumoral AdV-tk injection in three dose cohorts (maximum 10 viral particles) was performed during diagnostic staging, followed by a 14 day course of the prodrug valacyclovir, and subsequent surgery one week later...Thus, intratumoral AdV-tk injection into NSCLC proved safe, feasible, and effectively induced CD8 T cell activation. These data provide a foundation for additional clinical trials of GMCI for lung cancer patients with potential benefit if combined with other immune therapies.

All patients received prophylaxis with valaciclovir and cotrimoxazole. Nivo seemed to be effective and safe in a small number of patients who did not achieve CR after CAR T-cell therapy.

All patients received prophylaxis with valaciclovir and cotrimoxazole. Nivo seemed to be effective and safe in a small number of patients who did not achieve CR after CAR T-cell therapy.

All patients received prophylaxis with valaciclovir and cotrimoxazole. Nivo seemed to be effective and safe in a small number of patients who did not achieve CR after CAR T-cell therapy.

Valacyclovir was administered for 14 days, starting the day after AdV-tk injection. Intratumoral injection of AdV-tk into lung tumors was safe and feasible. Further, AdV-tk effectively induced peripheral blood and intra-tumoral CD8 T cell activation. Consequent upregulation of inhibitory receptors suggests a potential benefit for combination therapies.

All patients received prophylaxis with valaciclovir and cotrimoxazole. Nivo seemed to be effective and safe in a small number of patients who did not achieve CR after CAR T-cell therapy.

An alemtuzumab safety switch has also been established to ensure the elimination of CAR T cells following tumor eradication...Patient received a total dose of 3x10^6 /kg single dose CAR T cells, following which fluconazole and valacyclovir were administrated for infection prophylaxis...Conclusion Our first-in-human clinical trial demonstrates promising efficacy of CD4 CAR T cell therapy in treating patients with refractory Sezary syndrome. cCAR is able to eradicate leukemia blasts, exerting a profound tumor killing effect that is superior to traditional chemotherapies.